Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women. (15th January 2017)

• Record Type: Journal Article
• Authors: Vitale, Cristiana; Mammi, Caterina; Gambacciani, Marco; Russo, Novella; Spoletini, Ilaria; Fini, Massimo; Volterrani, Maurizio; Rosano, Giuseppe M.C.
• Is Part Of: International journal of cardiology. Volume 227(2017)
• Page Start: 217
• Page End: 221
• Publication Date: 2017-01-15
• Subjects: Hormone replacement therapy -- Prognosis -- Endothelial function -- Drospirenone -- Pulse wave velocity -- Augmentation index; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.11.149
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Drospirenone (DRSP) is an antialdosterone agent with progestogenic and antiandrogenic effects. This compound, has been recently used in combination with 17β-estradiol (E2) as hormonal therapy in postmenopausal women and has been shown to exert a significant antihypertensive effect in hypertensive post-menopausal women. Aim of the present study was to compare the effect of DRSP/E2 with those of Tibolone (T) on endothelial function, arterial stiffness, and lipid profile of early postmenopausal women naïve on post-menopausal hormonal therapy. Twenty-four women met the inclusion criteria and entered the study. Women were randomized to receive either DRSP/E2 or T for 6 months. Blood pressure and heart rate were similar in both groups at baseline and at the end of the study. Compared to baseline, endothelial function assessed by Reactive Hyperemia (RH) significantly improved in women receiving E2/DRSP, whereas no significant differences between baseline and follow up were detected in women receiving Tibolone. Women receiving E2/DRSP showed a significant decrease in pulse wave velocity and Augmentation Index compared to baseline while no changes were observed in women receiving Tibolone. The capacity of sera to trigger endothelial cells apoptosis in vitro measured by cell death assay was significantly reduced by E/DRSP but not by T (HFA-E 70 ± 5, 6% vs HFD-E 41 ± 4, 5%, p < 0, 001). In conclusion, the present study shows that the association of Estradiol and Drospirenone as hormonal replacement therapy significantly improves vascular parameters and the composition of sera relevant for vascular protection in early post-menopausal normotensive women. These effects are not shared by Tibolone.